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Abstract  
BACKGROUND: Insulin resistance (IR) is closely associated with diabetes mellitus. On the other 
hand, increased visceral fat in menopause is also associated with IR, which makes 
postmenopausal diabetic women in a big risk for cardiovascular diseases. There are conflicting 
reports about the effects on hormone replacement therapy (HRT) on IR.  
AIM: The aim of the study was to investigate the effects of HRT on IR.  
METHODS: A total of 40 postmenopausal women with type 2 diabetes were enrolled and followed 
for 12 months. Half of them were assigned to take HRT, while the other half made the control 
group. Fasting plasma glucose (FPG) and insulinemia were measured in both groups at baseline 
and after 12 months. IR was represented by Homeostatic model assessment for IR (HOMA-IR).  
RESULTS: HRT was associated with significant decrease in HOMA-IR, FPG and insulinemia in the 
examined group. There was no significant reduction in FPG and no significant increase in 
insulinemia levels and HOMA-IR values in control group after 12 months.  
CONCLUSION: HRT was associated with statistically signifficant increase of insulin sensitivity. 
Larger clinical trials will be necessary to understand whether HRT may improve insulin resistance 
and glucose homeostasis in women with diabetes, especially when given shortly after entering 
menopause. 
 
 
 
 
 
Introduction 
 
Postmenopausal estrogen therapy and 
estrogen plus progesterone hormone replacement 
therapy (HRT) alleviate symptoms of menopause and 
attenuate bone loss [1]. Moreover, several 
observational studies suggest that use of estrogen 
replacement therapy decreases the risk of coronary 
heart disease [2-4] and lowers overall mortality rates 
[5, 6]. 
The menopause transition, as well as the 
early postmenopausal period, is associated with an 
increase in total and central obesity [7-9]. Increased 
visceral fat is associated with insulin resistance [10], 
and this preferential storage of abdominal fat may 
contribute to cardiovascular disease and diabetes in 
postmenopausal women. Estrogen and HRT may 
improve fat distribution in postmenopausal women by 
preventing the increase in central body fat [7, 11-13]. 
However, the evidence concerning the effects of HRT 
on glucose homeostasis is controversial. Estrogen 
replacement therapy has been reported to have no 
effect on insulin sensitivity in postmenopausal women 
[14-16] and to improve carbohydrate metabolism in 
individuals with type 2 diabetes [18, 19]. In contrast, 
nondiabetic women taking estrogen alone were more 
insulin-resistant than women not on HRT or women 
taking estrogen and HRT [19]. Differences in the study 
population, type and route of administration of 
hormone therapy, and method of measuring insulin 
sensitivity may explain the disparate results of 
estrogen replacement on glucose metabolism. 
Individuals with insulin resistance require 
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increasing levels of insulin to maintain normal glucose 
levels and are likely to progress to type 2 diabetes 
mellitus [20]. Insulin resistance is often measured by 
using the homeostasis model assessment–insulin 
resistance (HOMA-IR) equation, which is a function of 
the product of fasting insulin and glucose levels 
[21]. Fasting insulin levels are the major indicator of 
insulin resistance and are increased by obesity and 
decreased with higher degree of physical activity 
[22]. Despite the potential advantages of measures of 
insulin resistance, the prognostic value of such 
measurements has not been extensively evaluated. 
Estimation of insulin resistance using either levels of 
insulin, HOMA-IR, glucose, or the ratio of triglycerides 
and high-density lipoprotein-cholesterol (TG/HDL-C) 
could potentially improve on cardiovascular risk 
stratification [23]. 
Insulin resistance and hyperinsulinemia are 
clinically important since the effects of insulin have 
been shown in the formation of atherosclerotic 
plaques, [24] and, hence, increased risk of 
hypertension and atherosclerosis has been attributed 
to insulin resistance in postmenopausal women. In 
these women, fasting glucose and insulin levels 
decrease with HRT [25]. It has been postulated that 
insulin resistance could decrease with HRT use [26]. 
Different studies resulted in different conclusions; 
estrogen and progesteron were shown to decrease 
insulin sensitivity in one study [27], but were reported 
not to affect insulin sensitivity in others [27, 28]. 
For this reason, we aimed to study the effects 
of HRT on IR by the HOMA - IR 
 
 
Patients and Methods 
 
We prospectively studied 40 women in natural 
menopause with type 2 diabetes. Diabetes was 
diagnosed using the criteria of the World Health 
Organization, at least 2 years before entering the 
study. In order to maintain their glucose levels in an 
acceptable range, women with type 2 diabetes were 
on dietary management alone (two patients) or taking 
oral anti‐diabetic drugs that consisted of metformin 
and sulfonylureas (38 patients). Each diabetic patient 
received a diabetic diet of 1300 ckal/day. The women 
were instructed not to change their diet. None of them 
were taking insulin. None of the women were taking 
anti‐lipidaemic, corticosteroid or anti‐convulsant 
therapy. The anti‐diabetic medications were left 
unchanged during the study. 
Menopause was confirmed by the absence of 
menstruation for at least 12 months and by high 
serum levels of FSH (> 30 mIU/ml) and low serum 
levels of estradiol (E2) (< 20 pg/ml). The subjects had 
not received HRT previously. Gynaecological 
examination and mammogram were normal in all 
subjects. 
Half of the subjects (20 women) were 
assigned to take HRT (DM – HRT) group. The other 
half (20 women) made the control group, not taking 
HRT (DM – non HRT group). The randomisation of 
the subjects has been done upon base of willingness 
and motivation to cooperate. Subjects in the DM - 
HRT group had been taking oral HRT consisting of 
17β - estradiol (E2) 1 mg and DRSP (drospirenone) 2 
mg - Angeliq®, Schering AG, Germany, 1 tablet daily 
for 12 months. Subjects in DM – non HRT group were 
followed the same way as examined group. Exclusion 
criteria in both groups included 1) hypertension 
(systolic blood pressure ≥ 140 or diastolic blood 
pressure ≥ 90 mmHg); 2) anemia; 3) various degrees 
of renal insufficiency; 4) evidence of significant liver 
disease; and 5) hysterectomy or a history of recent 
surgery and who demonstrated significant chronic 
alcohol intake, were also excluded. All patients in this 
study gave written informed consent. 
This work was approved by the local medical 
ethics committee and all participants gave informed 
consent before the onset of study. 
All of the participants enrolled in our study 
have been contacted by telephone in three months + 
interval in order to discover any adverse effect of 
HRT. All metabolic and physical examinations were 
performed at the onset of the study and then again 
after 12 months of receiving HRT. Blood samples 
were taken after a 12 h fast. HbA1C was 
determined on an Cobas c 111 analyzer using 
commercial kits supplied from Roche Diagnostic 
Gmbh (Switzerland), and glucose levels were 
determined in an Beckman Analyzer 2 automated 
analyser by using commercial kits supplied from 
Analox Instruments Ltd, London (UK). Insulinemia 
was determined in an Elecsys 2010 analyzer using 
commercial kits from Roche Diagnostics Gmbh 
(Switzerland). 
 
Assessment of IR  
In primary analysis, we evaluated degrees of 
IR by homeostatic model assessment for IR (HOMA-
IR) using the formulas HOMA-IR = glucose × 
insulin/22.5. A higher HOMA-IR value indicates 
greater IR. 
 
Statistical analysis 
Statistical analysis was carried out with 
descriptive statistics, t - test for related samples and t 
- test for independent samples. The data are 
expressed as means ± SEM. Statistical significance 
was set at P < 0.05. Data were analysed using 
Statistica, version 10.0 ( StatSoft). 
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Results 
 
All of the women who were enrolled into the 
investigation completed the study. The mean age of 
the subjects was 49.3 ± 0.34 and 48.5 ± 3.1 years, 
and their mean body mass index (BMI) was 27.27 ± 
3.32 and 28.3 ± 2.4 kg/m
2
 in the DM‐HRT and DM 
non-HRT groups respectively. High school educated 
was 58.3 % and 54.2 %. The baseline characteristics 
of the subjects are given in Table 1. Two subjects in 
the DM‐HRT group and one subject in the DM 
non‐HRT group complained about abnormal vaginal 
bleeding such as metrorrhagia and four patients 
reported breast tenderness in the DM‐HRT group. 
Other adverse effects were not seen  
Table 1: Baseline characteristics of postmenopausal women by 
HRT status 
 
Women on HRT           
(n = 20) 
Women not on HRT      
(n = 20) 
P 
Age (years) 49 ± 3.34 48.5 ± 3.1 N/S 
BMI (kg/m
2
) 27 ± 3.32 28.3 ± 2.4 N/S 
Fasting plasma glucose 
(mmol/l) 
7.8 ± 0.86 8.0 ± 0.9 N/S 
HbA1C (%)  7.6 ± 0.54 7.9 ± 0.5 N/S 
Insulinemia( µU/ml ) 12.2 ± 3.41 12.3 ± 3.2 N/S 
HOMA – IR (µU/ml-mmol/l) 4.23 ± 1.7 4.31 ± 1.8 N/S 
N/S for P value – not statistically significant 
 
There was no statistically significance 
between two groups at baseline. HRT was associated 
with statistically significant decreases in serum fasting 
glucose, HbA1C, insulinemia levels and HOMA – IR 
values in the DM - HRT group. There was no 
significant reduction in glucose levels and HbA1C 
together with no significant increase in insulinemia 
levels and HOMA-IR values in the DM non-HRT group 
throughout 12 months.  
Table 2: Effects on HRT on Fasting Plasma Glucose (FPG), 
HbA1C, Insulinemia & HOMA - IR  
 
Women on 
HRT (n = 
20) 
P value 
Women not 
on HRT 
(n = 20) 
P value P* value 
FPG (mmol/l)  
Baseline 
12 months 
 
7.8 ± 0.86 
6.9 ± 0.6 
 
p< 0.001 
 
 
8.0 ± 0.9 
7.8 ± 1.1 
 
P=0.66 
 
P*< 0.0001 
HbA1C % 
Baseline 
12 months 
 
7.6 ± 0.54 
7.2± 0.43 
 
p<0.001 
 
 
7.9 ± 0.5 
7,7 ± 0.4 
 
 
p=0.477 
 
P*< 0.0001 
Insulinemia 
(µU/ml ) 
Baseline 
12 months 
 
 
12.2 ± 3.41 
10.4 ± 2.92 
 
 
 
p<0.001 
 
 
 
12.3 ± 3.2 
13.1 ± 3.7 
 
 
p= 0.08 
 
P*<0.0001 
HOMA – IR 
(µU/ml-mmol/l) 
Baseline 
12 months 
 
 
 
4.23 ± 1.7 
3.18 ± 1.4 
 
 
 
P<0.001 
 
 
4.31 ± 1.8 
4.54 ± 1.7 
 
 
P=0.69 
 
 
P*<0.0001 
P < 0.05 statistically significant for all postmenopausal women included in adequate group 
at baseline and after 12 months; P* < 0.05 statistically significant for group comparison at 
12 months. 
 
Regarding group comparison after 12 months, 
there was statistically significance noted in all 
examined parameters. Namely, there was statistically 
significant increase of FPG, HbA1C, insulinemia and 
HOMA - IR between DM – HRT group and DM – non 
HRT group after 12 months. The changes in serum 
fasting glucose, HbA1c levels, fasting insulin levels 
and HOMA-IR are given in Table 2. 
 
 
Discussion 
 
The results of the current study indicate that 
use of HRT in postmenopausal women contributes to 
the variability in insulin sensitivity observed in diabetic 
postmenopausal women. Specifically, women taking 
oral estrogen plus progesterone have higher glucose 
utilization and insulin sensitivity than women who 
were not on HRT. Similar to our findings, several 
studies suggest that estrogen replacement therapy 
improves glucose homeostasis [29-31]. HRT - treated 
women had significantly lower fasting insulin levels 
than women not taking HRT [32]. Glucose utilization 
by the hyperinsulinemiceuglycemic clamp had a 
tendency to increase, and HbA1c significantly 
decreased after 3 months of oral estradiol therapy in 
postmenopausal women with type 2 diabetes and 
moderate hyperandrogenicity [33]. The dose of 
therapy may be important such that low doses of 
conjugated equine estrogen improved insulin 
sensitivity by ITT, but higher doses resulted in 
deterioration of insulin sensitivity [34].  
Other studies report that estrogen therapy 
does not affect carbohydrate metabolism [14-16, 35-
37). In the Postmenopausal Estrogen/Progestin 
Interventions Trial [14], women were given estrogen 
alone or one of three estrogen/ progestin regimens for 
3 years. Fasting insulin levels decreased 
nonsignificantly in women on active treatments, and 
changes in 2-h insulin did not differ between 
treatments or with the treatments. Furthermore, 
estrogen replacement therapy did not change HbA1c 
and insulin area under the OGTT curve in patients 
with diabetes [35, 36] or change glucose tolerance or 
glucose uptake by the hyperinsulinemiceuglycemic 
clamp in healthy postmenopausal women [15, 16]. 
Additional reports conclude that estrogen therapy 
may, in fact, worsen glucose homeostasis [32–35]. 
Randomized trials of postmenopausal women indicate 
that 6–18 months of HRT increase fasting insulin 
levels [33] and decrease insulin sensitivity using either 
the intravenous glucose tolerance test (IVGTT) [34] or 
the insulin tolerance test (ITT) [35]. 
 Differences in the study population (healthy 
versus diabetic postmenopausal women), type of 
therapy (estradiol versus the combination of estradiol 
plus progestin), and method of measuring insulin 
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sensitivity (fasting insulin concentrations, OGTT, ITT, 
IVGTT, glucose clamp) may explain the disparate 
results of HRT on glucose metabolism. Moreover, the 
route of estrogen administration may contribute to 
discrepancies in findings such that transdermal 
therapy may [15] or may not affect glucose 
metabolism [36, 37]. However, because none of the 
women in our study were using transdermal estradiol 
therapy, this does not contribute to the differences in 
glucose utilization observed.  
The mechanism by which estrogen treatment 
may alter insulin action in humans is not completely 
understood. Similar to our results, animal studies 
would suggest that estradiol maintains or improves 
insulin sensitivity. Estrogen has been shown to 
increase glucose transport and glucose utilization in 
muscle cells of animals [38, 39]. Estrogen regulates 
insulin-induced glucose transport [40] through glucose 
transporter translocation in rat skeletal muscle [41]. 
Moreover, in oophorectomized rats, there is a 
reduction in insulin-stimulated translocation of GLUT4 
to the plasma membrane as well as a reduction in 
glycogen synthase protein expression in skeletal 
muscle, which contributes to a decrease in whole-
body insulin sensitivity [41]. We are unaware of any 
studies examining skeletal muscle glucose transport 
in postmenopausal women on or not on HRT. Based 
on the literature, which suggests that GLUT4 levels do 
not vary between normal lean glucose-tolerant and 
obese diabetic subjects [42], we would not expect 
differences in skeletal muscle GLUT4 protein between 
women taking estrogen, on HRT, or not on HRT. 
However, it is possible that glycogen synthase, 
GLUT4 translocation, and/or other early steps in the 
insulin-signaling pathway change are altered with the 
use of estrogen or estrogen plus progesterone in 
women. In addition, another potential mechanism of 
estrogen on insulin sensitivity could be mediated 
through estrogen’s effect on peripheral vascular 
reactivity [43, 44]. 
In conclusion, our results show that women 
taking oral HRT are more insulin sensitive than non-
hormone users. Additional studies with longer duration 
and more subjects are needed to determine the 
cellular mechanisms that could account for the 
differences in insulin sensitivity between 
postmenopausal women who are taking estrogen, on 
combined hormonal therapy, or not on HRT.  
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